Adult: 20 mg once daily via slow inj over at least 3 minutes or infusion over 10-30 minutes. Switch to oral therapy as soon possible.
Intravenous Gastric and duodenal ulcers
Adult: Prophylaxis of rebleeding following therapeutic endoscopy: 80 mg via infusion over 30 minutes, may be followed by 8 mg/hour continuous infusion over 72 hours, then may switch to oral therapy given as 40 mg once daily for 4 weeks.
Intravenous Gastroesophageal reflux disease
Adult: Erosive reflux oesophagitis: 40 mg once daily. Symptomatic treatment of GERD: 20 mg once daily. Doses are given via slow inj over at least 3 minutes or infusion over 10-30 minutes. Switch to oral therapy as soon possible. Child: 1-11 years 10 mg once daily. 12-18 years 20 mg once daily. Switch to oral therapy as soon possible.
Oral NSAID-associated ulceration
Adult: 20 mg once daily for 4-8 weeks.
Oral Prophylaxis of NSAID-induced ulcers
Adult: 20 or 40 mg once daily for up to 6 months.
Oral Zollinger-Ellison syndrome
Adult: Initially, 40 mg bid, may be individually adjusted according to response. Usual range: 80-160 mg daily may be increased up to 240 mg daily if necessary. Daily doses >80 mg should be given in 2 divided doses.
Oral Eradication of H. pylori associated with peptic ulcer disease
Adult: 20 mg bid for 7 days, or 40 mg once daily for 10 days given as a triple therapy in combination with amoxicillin and clarithromycin. Child: >4 years <30 kg: 10 mg bid; ≥30 kg: 20 mg bid. All doses are given in combination with amoxicillin and clarithromycin for 7 days.
Oral Gastroesophageal reflux disease
Adult: Erosive reflux oesophagitis: 20 or 40 mg once daily for 4 weeks, may extend for further 4 weeks if necessary. Maintenance (to prevent relapse of healed erosive oesophagitis): 20 mg once daily for up to 6 months. Symptomatic treatment of GERD (without oesophagitis): 20 mg once daily for 4 weeks; assess treatment if symptoms do not resolve after 4 weeks, may extend for further 4 weeks if necessary. Child: 1-11 years Erosive reflux oesophagitis: ≥10 kg- <20 kg: 10 mg once daily for 8 weeks; ≥20 kg: 10 or 20 mg once daily for 8 weeks. Maintenance (to prevent relapse of healed oesophagitis): 10 mg once daily. Symptomatic treatment of GERD without oesophagitis: 10 mg once daily for up to 8 weeks. 12-18 years Same as adult dose.
Special Patient Group
CYP2C19 is the main enzyme responsible in esomeprazole metabolism and to a lesser extent the CYP3A4 isoenzyme.
CYP2C19 ultrarapid metabolisers (carriers of 2 increased function alleles e.g. *17/*17)
Patient may have insufficient therapeutic response to esomeprazole. Increase esomeprazole dose by 50-100% when used for eradication of H. pylori and monitor for risk of therapeutic failure. For other indications, may also consider increasing the dose by 50-100%.
CYP2C19 poor metabolisers (carriers of loss-of-function allele *2 e.g. *2/*2, *2/*3, *3/*3)
Patient may be exposed to higher esomeprazole levels. However, dosage adjustment may not be necessary. The incidence of this CYP2C19 phenotype varies and is estimated at 3% in Caucasians and 15-20% in Asians.
Currently, recommendations for CYP2C19 genetic testing in esomeprazole treatment have not been provided.
Severe: Max: 20 mg daily.
Intravenous Gastric and duodenal ulcers: Severe (Child-Pugh class C): 80 mg via infusion over 30 minutes, may be followed by 4 mg/hour continuous infusion over 72 hours.
Delayed-Release Cap: Should be taken on an empty stomach. Take 1 hr before meals. Tab: May be taken with or without food.
IV inj: Reconstitute vial labelled as 20 mg or 40 mg with 5 mL 0.9% NaCl. IV infusion (10-30 minutes): Reconstitute vial with 5 mL of 0.9% NaCl, lactated Ringer’s inj or 5% dextrose in water, then further dilute to reach final volume of 50 mL. IV infusion (loading dose and continuous infusion): Reconstitute 2 vials labelled as 40 mg with 5 mL normal saline each, then further dilute the 2 vials in 100 mL normal saline.
Concomitant use with rilpivirine, atazanavir, and nelfinavir.
Patient with gastric malignancy, reduced body stores or risk factors for reduced vitamin B12 absorption, or those at risk of fractures and osteoporosis. Severe renal and hepatic impairment. Children. Pregnancy and lactation. CYP2C19 ultrarapid metabolisers.
Significant: Hypomagnesaemia, osteoporosis-related fractures, fundic gland polyp, subacute cutaneous lupus erythematosus, SLE, acute interstitial nephritis, atrophic gastritis, Clostridium difficile-associated diarrhoea, gastrointestinal infections (e.g. Salmonella, Campylobacter), vitamin B12 deficiency (long-term therapy). Blood and lymphatic system disorders: Rarely, leucopenia, thrombocytopenia. Eye disorders: Blurred vision. Gastrointestinal disorders: Flatulence, diarrhoea, nausea, abdominal pain, vomiting, constipation, xerostomia. General disorders and admin site conditions: Inj site reactions, fever, malaise. Hepatobiliary disorders: Increased liver enzymes. Rarely, hepatitis. Immune system disorders: Rarely, hypersensitivity reactions (e.g. angioedema, anaphylactic shock, urticaria). Investigations: Altered thyroid hormone levels, increased gastrin, increased serum creatinine. Metabolism and nutrition disorders: Peripheral oedema. Rarely, hyponatraemia. Musculoskeletal and connective tissue disorders: Arthralgia, myalgia, weakness. Nervous system disorders: Headache, dizziness, drowsiness, vertigo, paraesthesia. Psychiatric disorders: Insomnia, agitation, confusion, depression. Reproductive system and breast disorders: Very rarely, gynaecomastia. Respiratory, thoracic and mediastinal disorders: Cough, bronchospasm. Skin and subcutaneous tissue disorders: Pruritus, rash, dermatitis. Rarely, alopecia.
This drug may cause dizziness and blurred vision, if affected, do not drive or operate machinery.
Monitor serum Mg levels prior to treatment initiation and periodically thereafter. Assess for signs or symptoms of rebleeding, bone fractures, and Clostridium difficile-associated diarrhoea (CDAD).
Symptoms: Weakness, confusion, headache, drowsiness, tachycardia, nausea, diaphoresis, flushing, dry mouth and other gastrointestinal symptoms. Management: Symptomatic and supportive treatment.
Increased risk of digoxin-induced cardiotoxic effects. May diminish the therapeutic effects of clopidogrel. Increased risk of hypomagnesaemia with diuretics. May increase serum concentrations of tacrolimus, methotrexate, cilostazol, and drugs metabolised by CYP2C19 (e.g. diazepam, citalopram, imipramine, phenytoin). May reduce absorption of ketoconazole, itraconazole, Fe salts, erlotinib. Concomitant use with warfarin may increase INR and prothrombin time. Esomeprazole serum levels may be decreased with CYP2C19 or CYP3A4 inducers (e.g. rifampicin) and increased with CYP3A4 inhibitors (e.g. voriconazole, clarithromycin). May prolong elimination half-life of cisapride. Potentially Fatal: May substantially decrease the serum levels of atazanavir, nelfinavir, or rilpivirine which may lead to the development of drug resistance.
Decreased serum concentrations with St. John’s wort.
May increase serum chromogranin A (CgA) levels causing false-positive result in diagnostic test for neuroendocrine tumours.
Description: Esomeprazole, the S-isomer of omeprazole, is a substituted benzimidazole proton pump inhibitor (PPI) that blocks the final step in gastric acid secretion by specific inhibition of H+/K+-ATPase enzyme system present on the secretory surface of the gastric parietal cells. Pharmacokinetics: Absorption: Rapidly absorbed from the gastrointestinal tract. Delayed and reduced absorption with food. Bioavailability: Approx 64% (single dose); approx 89% (repeated dose). Time to peak plasma concentration: Approx 1-2 hours. Distribution: Plasma protein binding: Approx 97%. Metabolism: Extensively metabolised in the liver primarily by CYP2C19 isoenzyme to form inactive hydroxy and desmethyl metabolites, and to a lesser extent by CYP3A4 isoenzyme to sulfone metabolite. Excretion: Mainly via urine (approx 80% as inactive metabolites; <1% as unchanged drug); faeces (20%). Elimination half-life: Approx 1-1.5 hours.
Store between 20-25°C. Protect from light and moisture.
A02BC05 - esomeprazole ; Belongs to the class of proton pump inhibitors. Used in the treatment of peptic ulcer and gastro-oesophageal reflux disease (GERD).
Dean L. Esomeprazole Therapy and CYP2C19 Genotype. Medical Genetics Summaries [Internet]. Bethesda (MD):National Center for Biotechnology Information (US). Accessed 22/05/2019. PMID: 28520354Annotation of DPWG Label for Esomeprazole and CYP2C19. Pharmacogenomics Knowledgebase (PharmGKB). https://www.pharmgkb.org/. Accessed 30/04/2019.Annotation of EMA Label for Esomeprazole and CYP2C19. Pharmacogenomics Knowledgebase (PharmGKB). https://www.pharmgkb.org/. Accessed 30/04/2019.Annotation of FDA Label for Esomeprazole and CYP2C19. Pharmacogenomics Knowledgebase (PharmGKB). https://www.pharmgkb.org/. Accessed 30/04/2019.Annotation of HCSC Label for Esomeprazole and CYP2C19. Pharmacogenomics Knowledgebase (PharmGKB). https://www.pharmgkb.org/. Accessed 30/04/2019.Anon. Esomeprazole. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. https://www.ahfscdi.com. Accessed 30/04/2019.Anon. Esomeprazole. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 30/04/2019.Buckingham R (ed). Esomeprazole. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 30/04/2019.Esomeprazole 40 mg Powder for Solution for Injection/Infusion (Sun Pharmaceuticals Industries Europe B.V.). MHRA. https://products.mhra.gov.uk/. Accessed 30/04/2019.Esomeprazole Magnesium - Capsule, Delayed Release Pellets (Mylan Pharmaceuticals Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 30/04/2019.Joint Formulary Committee. Esomeprazole. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 30/04/2019.Ventra 20 mg Gastro-Resistant Capsules, Hard (Ethypharm). MHRA. https://products.mhra.gov.uk/. Accessed 30/04/2019.